Cullinan Therapeutics Reports Phase 1 Trial Data for CLN-049 with 19% and 21% CRc Rates in AML and MDS Patients

Cullinan Therapeutics shared updated Phase 1 dose-escalation data for CLN-049 in patients with relapsed or refractory AML or MDS. At the data cutoff, 87 patients—76 with AML and 11 with MDS—were enrolled across 13 cohorts; the stated target dose range is 1.5–24 µg/ (unit as provided). The supplied article text contains no efficacy or safety results.